May 28, 2024
8th BOSTON BIOTECHNOLOGY SUMMIT™ The Boston Paris Biotechnology Summit™ 2024, a key in-person meeting, also Live Streamed internationally brought Two Hundred (n=200) biopharmaceutical professionals [50% CEO and C-level Executives] to CIC CAMBRIDGE, 02142 Cambridge MA, 15 May 2024 to discuss the Economy & Investment, showcased Award-Winning...
December 11, 2023
Selected 2023 projects and workflows (alphabetically ordered): BIOPHTA (Paris, France). US Executive Advisor. BIOPHTA aims to radically change eye treatments for various ophtalmological diseases that require daily eye drops or repeated intraocular injections. BIOPHTA technology of drug delivery improve treatment efficacy by leveraging a micro...
June 8, 2023
Summit Mission An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, and regional clusters, institutional, philanthropic and strategic investors. The Summit’s intent is to spark projects, their financings and strategic deals to solve unmet medical needs...
January 3, 2023
[ACTICOR-BIOTECH, Paris, France] US Medical Executive @ Acticor-Biotech ACTISAVE Study – ClinicalTrials.gov Identifier: NCT05070260. Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke (ACTISAVE) DECOY Therapeutics, Cambridge, MA,...
July 20, 2022
Selected Projects listed in alphabetical order: [ACTICOR-BIOTECH, Paris, France] US Medical Executive for Acticor BiotechDeveloping Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.ACTISAVE phase II/III Study [(NCT05070260] ongoing.Please refer to : www.acticor-biotech.com [DECOY...
January 6, 2022
[ACTICOR-BIOTECH, Paris, France] US Operations’ Collaboration [Press Release] November 4, 2021 at 06:30 pm CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug Administration (FDA) has provided clearance for...
November 8, 2021
Shahin Gharakhanian had the honor to accept on behalf of ACTICOR-BIOTECH – the PRIX GALIEN MEDSTARTUP 2021 – Award in the «collaboration» category recognizing joint work with the Memorial Hermann Hospital in Houston, Tx. Ceremony held at the Alexandria Life Sciences Center in New York 28 Oct. 2021. We are developing Glenzocimab, a humanized...
October 12, 2021
Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray. Barbara Hibner*, Peter Marschel*, Frederick E. Pierce II*, Shahin Gharakhanian** *Research & Development Program Team, **Scientific Advisory Board, DECOY Therapeutics, CAMBRIDGE MA, USA. [Contact:...
July 27, 2021
* Utay, N. S., Asmuth, D. M, Gharakhanian, S., Contreras, M., Warner, C. D., & Detzel, C. J. (2021). Potential use of serum-derived bovine immunoglobulin/protein isolate for the management ofCOVID-19. Drug Development Research, 1–7. https://doi.org/10.1002/ddr.21841 * GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind,...
January 7, 2021
On 30 December 2019 a ProMed email from the International Society of Infectious Diseases (IDSA) contained information on <Undiagnosed pneumonia in China>, thus alerting the world to what was to become the worst health crisis in 100 years. On 24 January 2020, the New England Journal of Medicine (2020, 382: 727-733) published a brief report from...